Global Dalteparin Sodium Market Size By Type (Tablet, Injection), By Application (Myocardial Infarction Treatment, Hemodialysis), By Region, And Segment Forecasts, 2023 to 2032

The Global Dalteparin Sodium Market was valued at USD 1.4 billion in 2023 and is projected to reach USD 2.3 billion by 2031, growing at a CAGR of 6.5% during the forecast period from 2023 to 2031. Dalteparin sodium, a low molecular weight heparin (LMWH), is primarily used as an anticoagulant for preventing and treating deep vein thrombosis (DVT), pulmonary embolism, and as prophylaxis for venous thromboembolism in various medical and surgical conditions. The increasing prevalence of cardiovascular and thromboembolic disorders, along with a growing elderly population susceptible to these conditions, is propelling market growth.

Drivers:

1. Rising Incidence of Thromboembolic Diseases:

The global burden of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is on the rise. Dalteparin sodium’s efficacy and safety profile make it a preferred choice for clinicians in prophylactic and therapeutic settings.

2. Aging Population and Associated Risks:

As the global population ages, the incidence of conditions requiring anticoagulant therapy increases, notably among hospitalized and immobile patients. Dalteparin’s convenience of use and lower risk of complications compared to unfractionated heparin enhances its appeal in geriatric care.

3. Surgical and Cancer-Associated Prophylaxis:

Dalteparin is increasingly used in post-operative and oncology care settings due to its reliable anticoagulant effect and lower bleeding risk, making it a standard prophylactic agent in these high-risk groups.

Restraints:

1. Availability of Alternative Anticoagulants:

The market faces competition from newer oral anticoagulants (NOACs) like rivaroxaban and apixaban that do not require injections or regular monitoring, which may limit the adoption of injectable LMWHs like dalteparin sodium.

2. Risk of Bleeding and Contraindications:

Although safer than traditional heparins, dalteparin still carries bleeding risks and is contraindicated in patients with active bleeding or severe thrombocytopenia, which may restrict its usage in certain patient groups.

Opportunity:

1. Expansion in Emerging Healthcare Markets:

As healthcare infrastructure improves in Asia-Pacific, Latin America, and the Middle East, the availability and adoption of anticoagulants like dalteparin sodium are expected to grow, especially with increased awareness of thromboembolic risks.

2. Extended Use in Cancer-Related Thrombosis:

Clinical guidelines increasingly recommend LMWHs like dalteparin for managing cancer-associated thrombosis. This growing indication base offers a lucrative expansion opportunity for pharmaceutical manufacturers.

Market by System Type Insights:

Based on system type, the Injectable Formulations segment dominated the market in 2023. Dalteparin sodium is primarily administered subcutaneously, with its injectable format offering rapid action and dosage control. Innovations in prefilled syringes and auto-injectors are enhancing patient compliance and are expected to drive further adoption.

Market by End-use Insights:

In terms of end-use, the Hospital Pharmacy segment held the largest market share in 2023. The high prevalence of acute venous thromboembolism cases, surgical procedures, and cancer therapies in hospital settings makes these institutions the largest consumers of dalteparin sodium. Meanwhile, retail pharmacies are seeing rising demand from outpatient settings due to increasing long-term anticoagulant therapy.

Market by Regional Insights:

North America led the market in 2023, owing to well-established healthcare infrastructure, a high burden of thromboembolic diseases, and the presence of leading pharmaceutical companies. Asia-Pacific is projected to witness the fastest growth during the forecast period, driven by an aging population, increasing health awareness, and improvements in healthcare access in countries such as China and India.

Competitive Scenario:

Key players in the Global Dalteparin Sodium Market include Pfizer Inc., Aspen Pharmacare Holdings Limited, Accord Healthcare, Dr. Reddy’s Laboratories, Hikma Pharmaceuticals, and Mylan N.V. These companies are investing in product enhancements, regional expansion, and strategic partnerships. For example:

In 2023, Pfizer announced the expansion of its Fragmin (dalteparin sodium) production to meet rising global demand.

In 2024, Hikma Pharmaceuticals launched a biosimilar version of dalteparin in select European markets, aiming to reduce treatment costs and improve accessibility.

Scope of Work – Global Dalteparin Sodium Market

Report Metric Details

Market Size (2023) USD 1.4 billion

Projected Market Size (2031) USD 2.3 billion

CAGR (2023–2031) 6.5%

Market Segments By System Type, By End-use, By Region

Growth Drivers Aging population, rising thromboembolic cases, and oncology prophylaxis usage

Opportunities Expansion in emerging markets and extended cancer thrombosis use

Key Market Developments:

May 2023: Pfizer expanded Fragmin availability in new therapeutic areas in Europe and Asia, aiming to broaden its oncological and surgical prophylaxis coverage.

July 2024: Accord Healthcare received regulatory approval for a generic dalteparin formulation in Canada.

February 2025: Aspen Pharmacare entered into a strategic distribution agreement with healthcare providers in Latin America to increase dalteparin reach in low-income countries.

FAQs:

1. What is the current market size of the Global Dalteparin Sodium Market?

The Global Dalteparin Sodium Market was valued at USD 1.4 billion in 2023.

2. What is the major growth driver of the Global Dalteparin Sodium Market?

The major growth driver is the rising incidence of thromboembolic disorders and increased use in surgical and cancer-related prophylaxis.

3. Which is the largest region during the forecast period in the Global Dalteparin Sodium Market?

North America is the largest region due to advanced healthcare infrastructure and high disease burden.

4. Which segment accounted for the largest market share in the Global Dalteparin Sodium Market?

The Hospital Pharmacy segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Dalteparin Sodium Market?

Key players include Pfizer Inc., Aspen Pharmacare, Accord Healthcare, Hikma Pharmaceuticals, Dr. Reddy’s Laboratories, and Mylan N.V.

Let me know if you’d like this in a downloadable format!